Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 14
Submit an article Journal homepage
320
Views
4
CrossRef citations to date
0
Altmetric
Letters to the Editor

Retreatment with venetoclax and hypomethylating agents among AML patients who have relapsed after initial response and subsequent interruption of therapy

Tamer A. Othmana Gehr Family Center for Leukemia Research, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Medical Center, Duarte, CA, USA
,
Jianying Zhangb Department of Information Sciences, City of Hope Medical Center, Duarte, CA, USA
,
Matthew Meia Gehr Family Center for Leukemia Research, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Medical Center, Duarte, CA, USA
,
Anthony S. Steina Gehr Family Center for Leukemia Research, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Medical Center, Duarte, CA, USA
,
Stephen J. Formana Gehr Family Center for Leukemia Research, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Medical Center, Duarte, CA, USA
,
Guido Marcuccia Gehr Family Center for Leukemia Research, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Medical Center, Duarte, CA, USA
,
Vinod Pullarkata Gehr Family Center for Leukemia Research, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Medical Center, Duarte, CA, USA
&
Ibrahim Aldossa Gehr Family Center for Leukemia Research, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Medical Center, Duarte, CA, USACorrespondence[email protected]
 show all
Pages 3532-3533 | Received 20 Jul 2020, Accepted 04 Aug 2020, Published online: 19 Aug 2020
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days
"Retreatment with venetoclax and hypomethylating agents among AML patients who have relapsed after initial response and subsequent interruption of therapy." Leukemia & Lymphoma, 61(14), pp. 3532–3533

Disclosure statement

AS has served on Advisory boards for Stemline and Amgen, and on the Speaker Bureau for Stemline, Celgene and Amgen. GM is on Speaker’ bureau for Abbvie and Novartis, and serves on Advisory Board with Janssen Pharm. VP has served on the advisory boards for Abbvie and JAZZ Pharmaceuticals and is a member of Speakers bureau for JAZZ Pharmaceuticals, Amgen, Novartis and Abbvie. IA has served on the advisory board for Abbvie, Agios, and KiTE Pharma, consultant to Autolus Limited and served on the Speaker Bureau for JAZZ Pharmaceuticals. The remaining authors have no relevant conflict of interest.

Log in via your institution

Access through your institution

Log in to Taylor & Francis Online

Restore content access

Restore content access for purchases made as guest
Purchase options * Save for later

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,065.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.